Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO

NASDAQHealthcareMedical - Instruments & Supplies

Latest quote

$1.20

−$0.01 · -0.83%

Aug 21, 3:55 PM ET

BNGO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

45

Fair Value

Momentum

39

Weakening

Sentiment

38

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Albert A. Luderer
Listed since
Aug 21, 2018
Employees
96

Market position

Volume
193.21K
1.36× average
Average volume
141.62K
Average daily volume
Market cap
13.77M USD
Beta
1.62
Market reference 1

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
-665.83%
11 comparable reports
Latest EPS result
-0.64
Estimate -0.67 · Beat by 4.48%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-4.38-8.74-13.1Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual -12.14, estimate -5.9, surprise -105.75%, Miss. Q2 2025, reported May 14, 2025: actual -1.15, estimate -3.49, surprise +67.05%, Beat. Q3 2025, reported Aug 14, 2025: actual -1.99, estimate -2.69, surprise +26.02%, Beat. Q4 2025, reported Nov 13, 2025: actual -1.59, estimate -1.81, surprise +12.15%, Beat. Q1 2026, reported Mar 23, 2026: actual -0.03, estimate -0.81, surprise +96.30%, Beat. Q2 2026, reported May 13, 2026: actual -0.76, estimate -0.81, surprise +6.17%, Beat. Q3 2026, reported Aug 10, 2026: actual -0.64, estimate -0.67, surprise +4.48%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.45, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates8.78M7.74M6.7M5.66MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 8.16M USD, estimate 6M USD, surprise +36.05%, Beat. Q2 2025, reported May 14, 2025: actual 6.46M USD, estimate 6.25M USD, surprise +3.31%, Beat. Q3 2025, reported Aug 14, 2025: actual 6.73M USD, estimate 6.56M USD, surprise +2.58%, Beat. Q4 2025, reported Nov 13, 2025: actual 7.37M USD, estimate 6.91M USD, surprise +6.68%, Beat. Q1 2026, reported Mar 23, 2026: actual 7.95M USD, estimate 7.88M USD, surprise +0.91%, Beat. Q2 2026, reported May 13, 2026: actual 6.69M USD, estimate 6.57M USD, surprise +1.82%, Beat. Q3 2026, reported Aug 10, 2026: actual 8.17M USD, estimate 7.55M USD, surprise +8.20%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 8.44M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$46.50

3775.00% upside
Past 12 months12-month forecastHigh $175Average $46.50Low $1.00

Rating distribution

7 ratings
Strong buy00%
Buy457%
Hold343%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
Ladenburg ThalmanndowngradeBuyNeutral
BTIGmaintainBuy

BNGO news

BNGO peers

ETFs holding BNGO

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BNGO

research.disclaimer